Ross Stores, Inc. vs Sana Biotechnology Inc — how do they compare? Ross Stores, Inc. trades at $233.99 (market cap $75.63B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Ross Stores, Inc. is far larger — about 86.5× Sana Biotechnology Inc's market cap, and Ross Stores, Inc. pays a 0.75% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ROST | SANA | |
|---|---|---|
Market Cap | $75.63B | $873.84M |
Sector | Consumer Cyclical | Health |
52-Week High | $240.13 | $5.92 |
52-Week Low | $134.02 | $2.68 |
Enterprise Value | $76.23B | $848.03M |
Dividend Yield | 0.75% | — |
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $235.78, up 1.05% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q1 2026 results with 21% sales growth and expanding margins, while expanding its store footprint with 47 new locations in mid-2026. Valuation metrics show a P/E of 32.93 and robust profitability with a 38.98% ROE, though the stock trades near analyst price targets.
The outlook remains positive due to consistent earnings outperformance and store expansion, but risks include high valuation multiples and competitive retail pressures. Analyst consensus is bullish with a $259 price target, suggesting moderate upside potential from current levels amid broader market volatility.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Trailing returns across standard periods
Latest headlines on both assets
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →